Physicians back DTC ban

Share this article:
A solid majority of doctors— 64%—say there should be some sort of moratorium on DTC advertising, according to a survey by TNS Healthcare.

Almost half of physicians— 44%—would approve of a moratorium of two years or more, and 27% believe there should be no DTC ads at all.

Among specialists, cardiologists were the most hostile to DTC, with 73% favoring some type of moratorium, and endocrinologists close behind at 69%. Just 55% of neurologists and 60% of gastroenterologists agreed.

The survey found strong support among physicians for stricter policies around claims and product cautions and more severe penalties for false and misleading ads.

The survey of 1,002 physicians and 251 consumers found physician attitudes toward DTC far harsher than those of the general public.

Only 44% of consumers favored a moratorium on drug ads, with 41% backing a two-year moratorium and 32% saying there should be no drug advertising at all.

Physicians and consumers were in agreement that the FDA is falling down on the job of policing DTC, with three-quarters of both groups saying the agency has failed to adequately vet ads.—

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...